MedTrace Logo

S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer

NCT00003095 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2015-10-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy for breast cancer may damage the genes of cells. This may lead to the development of secondary cancers.

PURPOSE: Pilot study to evaluate the degree of gene damage following chemotherapy in women with stage II or stage III breast cancer involving four to nine axillary lymph nodes.

Conditions

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Marilyn L. Slovak, PhD · City of Hope Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-11-30
Primary Completion
2001-02-28
Completion
2001-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003095 on ClinicalTrials.gov